Abstract
The classic model of activation of telomerase, for which activity has been found in most cancers including cutaneous malignant melanoma (CMM), dictates that enzyme activity is generated by pathological reactivation of telomerase in telomerase-negative somatic cells. However, recent data demonstrated physiological up-regulation in some normal cell types when established as proliferating cultures, indicating that, in some cancer types, telomerase is expressed by the process of up-regulation in telomerase-competent precursor cells. In this study, cultures of epidermal melanocytes, progenitor cells of CMM, were established and harvested in the logarithmic phase of growth. Telomerase activity was looked for using a non-isotopic variant of the telomeric repeat amplification protocol, and transcript expression of the hTERT gene, the rate-limiting catalytic telomerase subunit, was investigated by the reverse transcription polymerase chain reaction. Neither telomerase activity nor hTERT mRNA could be detected in proliferating melanocyte cultures. Our in vitro data argue against the model of telomerase as a common biomarker of cell proliferation. The results further suggest that telomerase is tightly controlled in normal melanocytes, and that telomerase is reactivated rather than up-regulated in melanocytic precursors during melanoma initiation or progression. © 2000 Cancer Research Campaign
Similar content being viewed by others
Article PDF
Change history
16 November 2011
This paper was modified 12 months after initial publication to switch to Creative Commons licence terms, as noted at publication
References
Ackerman AB (1988) What naevus is dysplastic, a syndrome and the commonest precursor of malignant melanoma? A riddle and an answer. Histopathology 13: 241–256
Albino AP (1995) Genes involved in melanoma susceptibility and progression. Curr Opin Oncol 7: 162–169
Allsopp RC, Chang E, Kashefi AM, Rogaev EI, Piatyszek MA, Shay JW and Harley CB (1995) Telomere shortening is associated with cell division in vitro and in vivo. Exp Cell Res 220: 194–200
Balasubramanian S, Kim KH, Ahmad N and Mukhtar H (1999) Activation of telomerase and its association with G1-phase of the cell cycle during UVB-induced skin tumorigenesis in SKH-1 hairless mouse. Oncogene 18: 1297–1302
Belair CD, Yeager TR, Lopez PM and Reznikoff CA (1997) Telomerase activity: a biomarker of cell proliferation, not malignant transformation. Proc Natl Acad Sci USA 94: 13677–13682
Bosserhoff AK, Glaessl A, Stolz W and Buettner R (1997) Detection of telomerase activity in skin, melanocytic naevi, and melanoma by telomerase PCR ELISA. Biochemica 3: 16–18
Boyle P, Maisonneuve P and Doré J (1995) Epidemiology of malignant melanoma. Br Med Bull 51: 523–547
Briggs JC (1985) Melanoma precursor lesions and borderline melanomas. Histopathology 9: 1251–1262
Cong YS, Wen JP and Bacchetti S (1999) The human telomerase catalytic subunit hTERT: organization of the gene and characterization of the promoter. Hum Mol Genet 8: 137–142
Counter CM, Avilion AA, LeFeuvre CE, Stewart NG, Greider CW, Harley CB and Bacchetti S (1992) Telomere shortening associated with chromosome instability is arrested in immortal cells which express telomerase activity. EMBO J 11: 1921–1929
Counter CM, Gupta J, Harley CB, Leber B and Bacchetti S (1995) Telomerase activity in normal leucocytes and in hematologic malignancies. Blood 85: 2315–2320
Cramer SF (1991) The origin of epidermal melanocytes. Arch Pathol Lab Med 115: 115–119
Cuthbert AP, Bond J, Trott DA, Gill S, Broni J, Marriott A, Khoudoli G, Parkinson EK, Cooper CS and Newbold RF (1999) Telomerase repressor sequences on chromosome 3 and induction of permanent growth arrest in human breast cancer cells. J Natl Cancer Inst 91: 37–45
deLange T (1998) Telomeres and senescence: ending the debate. Science 279: 334–335
Dhaene K, Hübner R, Kumar-Singh S, Weyn B and Van Marck E (1998) Telomerase activity in human pleural mesothelioma. Thorax 53: 915–918
Dhaene K, Wauters J, Weyn B, Timmermans J-P and Van Marck E (1999) Expression profile of telomerase subunits in human pleural mesothelioma. J Pathol (in press)
Elwood JM and Jopson J (1997) Melanoma and sun exposure: an overview of published studies. Int J Cancer 73: 198–203
Feng J, Funk WD, Wang SS, Weinrich SL, Avilion AA, Chiu CP, Adams RR, Chang E, Allsopp RC, Yu J, Le S, West MD, Harley CB, Andrews WH, Greider CW and Villeponteau B (1995) The RNA component of human telomerase. Science 269: 1236–1241
Gilchrest BA, Park H-Y, Eller M and Yaar M (1998) The photobiology of the tanning response. In: The Pigmentary System: Physiology and Pathophysiology, Nordlund JJ, Boissy RE, Hearing VJ, King RA, Ortonne J-P (eds), pp. 359–372. Oxford University Press: New York
Glaessl A, Bosserhoff AK, Buettner R, Hohenleutner U, Landthaler M and Stolz W (1999) Increase in telomerase activity during progression of melanocytic cells from melanocytic naevi to malignant melanomas. Arch Dermatol Res 291: 81–87
Greaves M (1996) Is telomerase activity in cancer due to selection of stem cells and differentiation arrest. Trends Genet 12: 127–128
Greider CW (1998) Telomerase activity, cell proliferation, and cancer. Proc Natl Acad Sci USA 95: 90–92
Harle-Bachor C and Boukamp P (1996) Telomerase activity in the regenerative basal layer of the epidermis inhuman skin and in immortal and carcinoma-derived skin keratinocytes. Proc Natl Acad Sci USA 93: 6476–6481
Harley CB (1991) Telomere loss: mitotic clock or genetic time bomb. Mutat Res 256: 271–282
Harrington L, McPhail T, Mar V, Zhou W, Oulton R, Bass MB, Arruda I and Robinson MO (1997) A mammalian telomerase-associated protein. Science 275: 973–977
Hastrup N, Osterlind A, Drzewiecki KT and Hou-Jensen K (1991) The presence of dysplastic nevus remnants in malignant melanomas. A population-based study of 551 malignant melanomas. Am J Dermatopathol 13: 378–385
Holt SE, Wright WE and Shay JW (1996) Regulation of telomerase activity in immortal cell lines. Mol Cell Biol 16: 2932–2939
Holt SE, Aisner DL, Shay JW and Wright WE (1997) Lack of cell cycle regulation of telomerase activity in human cells. Proc Natl Acad Sci USA 94: 10687–10692
International Agency for Research on Cancer (1992). IARC monographs on the Evaluation of Carcinogenic Risks to Humans: Ultraviolet Radiation, Vol. 55, IARC: Lyon
Kim NW, Piatyszek MA, Prowse KR, Harley CB, West MD, Ho PL, Coviello GM, Wright WE, Weinrich SL and Shay JW (1994) Specific association of human telomerase activity with immortal cells and cancer. Science 266: 2011–2015
Kipling D (1995) The Telomere. Oxford University Press: Oxford
Kipling D (1997) Telomere structure and telomerase expression during mouse development and tumorigenesis. Eur J Cancer 33: 792–800
Klingel R, Mincheva A, Kahn T, Gissmann L, Dippold W, Meyer zum Buschenfelde KH and zur Hausen H (1987) An amplification unit in human melanoma cells showing partial homology with sequences of human papillomavirus type 9 and with nuclear antigen 1 of the Epstein–Barr virus. Cancer Res 47: 4485–4492
Kolquist KA, Ellisen LW, Counter CM, Meyerson M, Tan LK, Weinberg RA, Haber DA and Gerald WL (1998) Expression of TERT in early premalignant lesions and a subset of cells in normal tissues. Nat Genet 19: 182–186
Kreipe H, Wacker HH, Heidebrecht H-J, Haas K, Hauberg M, Tiemann M and Parwaresch R (1993) Determination of the growth fraction in non-Hodgkin’s lymphomas by monoclonal antibody Ki-S5 directed against a formalin-resistant epitope of the Ki-67 antigen. Am J Pathol 142: 1689–1694
Lambert J, Onderwater J, Vander Haeghen Y, Vancoillie G, Koerten HK, Mommaas AM and Naeyaert JM (1998) Myosin V colocalises with melanosomes and subcortical actin bundles not associated with stress fibers in human epidermal melanocytes. J Invest Dermatol 111: 835–840
Libow LF, Scheide S and DeLeo VA (1988) Ultraviolet radiation acts as an independent mitogen for normal human melanocytes in culture. Pigment Cell Res 1: 397–401
Mantell LL and Greider CW (1994) Telomerase activity in germline and embryonic cells of Xenopus. EMBO J 13: 3211–3217
Naeyaert JM, Eller M, Gordon PR, Park H-Y and Gilchrest BA (1991) Pigment content of cultured human melanocytes does not correlate with tyrosinase message level. Br J Dermatol 125: 297–303
Nakamura TM, Morin GB, Chapman KB, Weinrich SL, Andrews WH, Lingner J, Harley CB and Cech TR (1997) Telomerase catalytic subunit homologs from fission yeast and human. Science 277: 955–959
Nakayama J, Tahara H, Tahara E, Saito M, Ito K, Nakamura H, Nakanishi T, Ide T and Ishikawa F (1998) Telomerase activation by hTRT in human normal fibroblasts and hepatocellular carcinomas. Nat Genet 18: 65–68
Newbold RF, Overell RW and Connell JR (1982) Induction of immortality is an early event in malignant transformation of mammalian cells by carcinogens. Nature 299: 633–635
Pandita TK, Hall EJ, Hei TK, Piatyszek MA, Wright WE, Piao CQ, Pandita RK, Willey JC, Geard CR, Kastan MB and Shay JW (1996) Chromosome end-to-end associations and telomerase activity during cancer progression in human cells after treatment with alpha-particles simulating radon progeny. Oncogene 13: 1423–1430
Parris CN, Jezzard S, Silver A, MacKie R, McGregor JM and Newbold RF (1999) Telomerase activity in melanoma and non-melanoma skin cancer. Br J Cancer 79: 47–53
Quevedo WC and Fleischmann RD (1980) Developmental biology of mammalian melanocytes. J Invest Dermatol 75: 116–120
Ramakrishnan S, Eppenberger U, Mueller H, Shinkai Y and Narayanan R (1998) Expression profile of the putative catalytic subunit of the telomerase gene. Cancer Res 58: 622–625
Rhyu MS (1995) Telomeres, telomerase, and immortality. J Natl Cancer Inst 87: 884–894
Rudolph P, Knüchel R, Endl E, Heidebrecht H-J, Hofstädter F and Parwaresch R (1998) The immunohistochemical marker Ki-S2: cell cycle kinetics and tissue distribution of a novel proliferation-specific antigen. Mod Pathol 11: 450–456
Scheurlen W, Gissmann L, Gross G and zur Hausen H (1986) Molecular cloning of two new HPV types (HPV 37 and HPV 38) from keratoacanthoma and a malignant melanoma. Int J Cancer 37: 505–510
Takamiyagi A, Asato T, Nakashima Y and Nonaka S (1998) Association of human papillomavirus type 16 with malignant melanoma. Am J Dermatopathol 20: 69–73
Taylor RS, Ramirez RD, Ogoshi M, Chaffins M, Piatyszek MA and Shay JW (1996) Detection of telomerase activity in malignant and nonmalignant skin conditions. J Invest Dermatol 106: 759–765
Ueda M, Ouhtit A, Bito T, Nakazawa K, Lübbe J, Ichihashi M, Yamasaki H and Nakazawa H (1997) Evidence for UV-associated activation of telomerase in human skin. Cancer Res 57: 370–374
Ulaner GA, Hu JF, Vu TH, Giudice LC and Hoffman AR (1998) Telomerase activity in human development is regulated by human telomerase reverse transcriptase (hTERT) transcription and by alternate splicing of hTERT transcripts. Cancer Res 58: 4168–4172
Weterman MA, Van Muijen GN, Bloemers HP and Ruiter DJ (1994) Molecular markers of melanocytic tumor progression. Lab Invest 70: 593–608
Wright WE, Pereira SO and Shay JW (1989) Reversible cellular senescence: implications for immortalization of normal human diploid fibroblasts. Mol Cell Biol 9: 3088–3092
Wu K, Grandori C, Amacker M, Simon-Vermot N, Polack A, Lingner J and Dallafavera R (1999) Direct activation of TERT transcription by c-Myc. Nat Genet 21: 220–224
Wynford-Thomas D (1999) Cellular senescence and cancer. J Pathol 187: 100–111
Yamada O, Motoji T and Mizoguchi H (1996) Up-regulation of telomerase activity in human lymphocytes. Biochim Biophys Acta 1314: 260–266
Zhu X, Kumar R, Mandal M, Sharma HW, Dhingra U, Sokoloski JA, Hsiao R and Narayanan R (1996) Cell cycle-dependent modulation of telomerase activity in tumor cells. Proc Natl Acad Sci USA 93: 6091–6095
Author information
Authors and Affiliations
Rights and permissions
From twelve months after its original publication, this work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/
About this article
Cite this article
Dhaene, K., Vancoillie, G., Lambert, J. et al. Absence of telomerase activity and telomerase catalytic subunit mRNA in melanocyte cultures. Br J Cancer 82, 1051–1057 (2000). https://doi.org/10.1054/bjoc.1999.1041
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1054/bjoc.1999.1041